SRC and cancer: Our report of the SL relation between EPHB6 and SRC may help to overcome this problem, and improve the efficiency of SRC inhibiting approaches in cancer therapy by showing that treatment with SRC inhibitors should be personalized, and mostly applied to patients with reduced or missing EPHB6 expression.